A combination of autophagy inhibitor HCQ, CDK4/6 inhibitor Palbociclib, and the immune checkpoint programmed cell death-1 (PD-1)/Programmed death-ligand 1 (PD-L1) inhibitor avelumab to eradicate dormant breast cancer has entered a phase II clinical trial (NCT04841148). This evidence concerns the gene CDK4 and breast cancer.